Overall survival is improved in mucinous adenocarcinoma of the colon
- First Online:
- 291 Downloads
Debate persists regarding the relationship between mucin expression and outcome in colon cancer. This arises due to discrepancy in the definition of mucinous adenocarcinoma and the combination of both colon and rectal cancers in analyses. This study examines the relationship between increased mucin production and outcomes in colon cancer.
Cases were classified according to the World Health Organization classification of mucinous adenocarcinoma of the colon. Accordingly, tumors were categorized as either (a) mucinous adenocarcinoma of the colon (greater than 50 % of the extracellular matrix occupied by mucin) or (b) non-mucinous adenocarcinoma of the colon. Overall survival and disease-free survival were calculated. A stepwise Cox proportional hazards regression model was employed to determine the risk of death/disease recurrence. Kaplan–Meier estimates of overall survival and disease-free survival were plotted for each group and compared using a log-rank test.
On univariate analysis, mucinous adenocarcinoma was associated with reduced risk of death (P = 0.01). On multivariate analysis, mucinous adenocarcinoma was also associated with reduced risk of death (hazard ratio (HR) 0.33, 95 % confidence interval (CI) 0.14–0.79, P = 0.01). Kaplan–Meier estimates confirmed improved rate of survival in the mucinous vs. non-mucinous group (P = 0.01). Mucinous adenocarcinoma did not affect disease-free survival (HR 0.75, 95 % CI 0.46–1.21, P = 0.22). A comparison of Kaplan–Meier estimates for systemic recurrence demonstrated significant increases in systemic recurrence in the group with no mucin production (P = 0.04) but not for locoregional recurrence (P = 0.24).
Histopathological evidence of mucinous adenocarcinoma in colon cancer is associated with improved outcomes.
KeywordsColon cancer Mucin Survival
- 1.Jivapaisarnpong P, Boonthongtho K (2011) Clinicopathological characteristics of mucinous and non-mucinous adenocarcinoma in the colon and rectum in Rajavithi Hospital, Thailand. J Med Assoc Thai 94: S41–S45Google Scholar
- 5.Cancer Research UK (2010) Bowel cancer incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/bowel/incidence/lifetime
- 19.Ionilă M, Cl M, Pirici D, Mogoantă SS (2011) Mucinous adenocarcinoma of the colon—a histochemical study. Romanian J Morphol Embryol 52(3):783–790Google Scholar
- 22.Hamilton RT, Aaltonen L (2000) Pathology and genetic of tumors of the digestive system. World Health Organization classification of tumors. Available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/index.php
- 25.Willem VG, Marijnen CA, Nagtegaal ID, Meershoek-Klein KE, Putter H, Wiggers T (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582CrossRefGoogle Scholar
- 26.Culligan K, Remzi FH, Soop M, Coffey JC (2012) Review of nomenclature in colonic surgery—proposal of a standardized nomenclature based on mesocolic anatomy. Surgeon: Journal of the Royal Colleges of Edinburgh and Ireland 11:1–5Google Scholar
- 27.Culligan K, Coffey JC, Kiran RP, Kalady M, Lavery IC, Remzi FH (2012) The mesocolon: a prospective observational study. Colorectal Dis Off J Assoc Coloproctol G B Irel 14(4):421–428Google Scholar
- 36.Melis M, Hernandez J, Siegel EM et al (1991) Mucinous carcinoma—just another colon cancer. Dis Colon Rectum 36:49–54Google Scholar
- 42.Toumi A et al (2010) Epidemiological study, pathologic evaluation and prognostic factors of colorectal mucinous vs. non-mucinous adenocarcinoma (a series of 196 patients). Tunis Med 88(1):12–17Google Scholar
- 43.Allen A, Hutten D, Jeffrey P, Pearson P (1998) MUC2 gene product has barrier functions against organisms and particles. Int J Inflamm 30(7):797–801Google Scholar
- 44.De Gramont A, Hubbard J, Shi Q, O’Connell J, Buyse M, Benedetti J et al (2010) Association between disease-free-survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28(3):460–465PubMedCentralPubMedCrossRefGoogle Scholar